Pipeline
Advancing sub-20 nm therapeutics across oncology.
Pipeline Snapshot
A high-level overview of Sapu Nano’s clinical and preclinical programs.
| Program | Modality | Indication | Status |
|---|---|---|---|
| SAPU-003 Everolimus Deciparticle™ |
Sub-20 nm nanoparticle | Advanced Solid Tumors | Phase 1/2 |
| Next-Gen Deciparticles | Sub-20 nm nano-cytotoxics | Solid Tumors (multiple) | IND enabling studies |
SAPU-003 — Everolimus Deciparticle™
SAPU-003 is a next-generation mTOR inhibitor delivered via a sub-20 nm Deciparticle™ formulation designed for deeper tumor penetration and improved pharmacokinetics. The ongoing Phase 1/2 study evaluates safety and biological signals in advanced solid tumors.
Next-Generation Deciparticle™ Programs
Sapu Nano is expanding the Deciparticle™ platform to include next-wave nano-cytotoxic formulations, radiosensitizers, and immune-modulating combinations designed to reach treatment-resistant tumor compartments.
About Sapu Nano
Precision Nanomedicine · Sub-20nm Deciparticle™ Platform · Global Development
Sapu Nano develops sub-20nm Deciparticle™ therapeutics engineered for deeper tumor penetration, improved biodistribution, and optimized systemic exposure. Our platform supports next-generation oncology medicines, with programs advancing through early- and late-stage clinical development across solid tumors and rare pediatric diseases.
IMPORTANT LINKS
Our Office
Sapu Nano
10801 Thornmint Rd. Suite 150
San Diego, CA 92127
Phone: (858) 521-8037
info@sapunano.com